TMDX Stock Overview
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
TransMedics Group, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$60.03|
|52 Week High||US$64.36|
|52 Week Low||US$10.00|
|1 Month Change||10.15%|
|3 Month Change||12.44%|
|1 Year Change||163.87%|
|3 Year Change||241.47%|
|5 Year Change||n/a|
|Change since IPO||168.47%|
Recent News & Updates
Is TransMedics Group (NASDAQ:TMDX) Weighed On By Its Debt Load?Jun 12
Industry Analysts Just Upgraded Their TransMedics Group, Inc. (NASDAQ:TMDX) Revenue Forecasts By 26%May 08
The Consensus EPS Estimates For TransMedics Group, Inc. (NASDAQ:TMDX) Just Fell DramaticallyFeb 28
Is TransMedics Group (NASDAQ:TMDX) Using Debt Sensibly?Jan 03
Health Check: How Prudently Does TransMedics Group (NASDAQ:TMDX) Use Debt?Aug 30
When Will TransMedics Group, Inc. (NASDAQ:TMDX) Become Profitable?Apr 01
John Carey Is The Vice President of Operations of TransMedics Group, Inc. (NASDAQ:TMDX) And They Just Sold 100% Of Their SharesMar 14
Is TransMedics Group (NASDAQ:TMDX) Using Debt In A Risky Way?Mar 08
If You Had Bought TransMedics Group (NASDAQ:TMDX) Shares A Year Ago You'd Have Earned 31% ReturnsFeb 05
|TMDX||US Medical Equipment||US Market|
Return vs Industry: TMDX exceeded the US Medical Equipment industry which returned -22.9% over the past year.
Return vs Market: TMDX exceeded the US Market which returned -21.2% over the past year.
|TMDX Average Weekly Movement||10.4%|
|Medical Equipment Industry Average Movement||8.9%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: TMDX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: TMDX's weekly volatility (10%) has been stable over the past year.
About the Company
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers.
TransMedics Group, Inc. Fundamentals Summary
|TMDX fundamental statistics|
Is TMDX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TMDX income statement (TTM)|
|Cost of Revenue||US$20.20m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.32|
|Net Profit Margin||-58.78%|
How did TMDX perform over the long term?See historical performance and comparison